研究

肺大細胞神経内分泌癌

1999年、WHOが新しい肺癌組織分類を提示しました。その一つの特徴は、肺大細胞神経内分泌癌というカテゴリ－が存在することを明らかにしたことでした。肺大細胞神経内分泌癌は小細胞癌と同様、髙悪性度神経内分泌腫瘍として分類されるべき、予後不良なカテゴリーです。そして、2015年に改訂された新WHO分類では、小細胞癌や大細胞神経内分泌癌は、カルチノイドとともに「神経内分泌性腫瘍」としてまとめられました。当科は、この肺大細胞神経内分泌癌を中心とした研究を積極的に進めています。現在は、新しいエビデンスを世界に発信できるように病理学ならびに医療衛生学部の先生方と協力しながら研究を継続しています。

最近の関連した業績

  1. Iyoda A, Jiang SX, Travis WD, Kurouzu N, Amano H, Sato Y, Rusch VW, Saegusa M, Satoh Y. Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol Clin Oncol 2013; 1: 437-43.
  2. Ryuge S, Sato Y, Jiang SX, Wang G, Matsumoto T, Katono K, Inoue H, Iyoda A, Satoh Y, Yoshimura H, Masuda N. Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer 2012; 77: 415-20.
  3. Matsumoto T, Ryuge S, Kobayashi M, Kageyama T, Hattori M, Goshima N, Jiang SX, Saegusa M, Iyoda A, Satoh Y, Masuda N, Sato Y. Anti-HuC and -HuD autoantibodies are differential sero-diagnostic markers for small cell carcinoma from large cell neuroendocrine carcinoma of the lung. Int J Oncol 2012; 40: 1957-62.
  4. Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, Saegusa M, Rusch VW, Satoh Y. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Therap Med 2011; 2: 1041-5.
  5. Nasgashio R, Sato Y, Matsumoto T, Kageyama T, Hattori M, Iyoda A, Satoh Y, Ryuge S, Masuda N, Jiang SX, Saegusa M. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung. Lung Cancer 2011;74: 405-10.
  6. Hoshi R, Furuta N, Horai T, Ishikawa Y, Miyata S, Satoh Y. Discriminant Model for Cytologic Distinction of Large Cell Neuroendocrine Carcinoma from Small Cell Carcinoma of the Lung. J Thorac Oncol 2010; 5: 472-8.
  7. Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Ryuge S, Masuda N, Jiang SX, Okayasu I. Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. Pathol Intern 2010; 60: 71-7.
  8. Amin RM, Hiroshima K, Iyoda A, Hoshi K, Honma K, Kuroki M, Kokubo T, Fujisawa T, Miyagi Y, Nakatani Y.LKB1 protein expression in neuroendocrine tumors of the lung. Pathol Int. 2008;58:84-8.
  9. Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma.　Ann Thorac Surg 2007;84:702-7.
  10. 佐藤之俊,中川健．肺大細胞神経内分泌癌の現状とその後の展開. 日胸 2006;65: S10-5
  11. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, Tanizawa T, Fujisawa T, Nakatani Y. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006;19:1358-68.
  12. Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y, Fujisawa T. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006;82:1802-7.
  13. Iyoda A, Hiroshima K, Moriya Y, Sekine Y, Shibuya K, Iizasa T, Nakatani Y, Fujisawa T. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma.　J Thorac Cardiovasc Surg 2006;132:312-5.
  14. 伊豫田明, 廣島健三, 中谷行雄,藤澤武彦.肺大細胞神経内分泌癌. 肺癌 2006; 46:315-20.
  15. Yamada Y, Iyoda A, Suzuki M, Mizobuchi T, Baba M, Hiroshima K, Ohwada H, Fujisawa T. Double primary lung carcinoma consisting of large cell neuroendocrine carcinoma and squamous cell carcinoma: report of a case. Ann Thorac Cardiovasc Surg. 2005;11:397-400.
  16. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, Nakagawa K, Nomura H, Ishikawa Y. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363: 775-81.
  17. Iyoda A, Hiroshima K, Moriya Y, Mizobuchi T, Otsuji M, Sekine Y, Shibuya K, Iizasa T, Saitoh Y, Fujisawa T.　Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg. 2004 ;77:1891-5.
  18. Hiroshima K, Iyoda A, Shibuya K, Haga Y, Toyozaki T, Iizasa T, Nakayama T, Fujisawa T, Ohwada H.Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer. 2004;100:1190-8.
  19. Iyoda A, Baba M, Hiroshima K, Saitoh H, Moriya Y, Shibuya K, Iizasa T, Horiuchi F, Ohwada H, Fujisawa T. Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: Comparison with classic large cell carcinoma. Oncol Rep. 2004;11:285-8.
  20. Hiroshima K, Iyoda A, Shibuya K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg. 2002;73:1732-5.
  21. Iyoda A, Hiroshima K, Baba M, Saitoh Y, Ohwada H, Fujisawa T. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors.　Ann Thorac Surg. 2002;73:1049-54.
  22. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, Ohwada H.　Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 2001;92:1108-12.
  23. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H.　Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology.　Cancer. 2001;91:1992-2000.

ページTOPへ戻る